These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33446805)

  • 1. SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms.
    Wang Y; Mohseni M; Grauel A; Diez JE; Guan W; Liang S; Choi JE; Pu M; Chen D; Laszewski T; Schwartz S; Gu J; Mansur L; Burks T; Brodeur L; Velazquez R; Kovats S; Pant B; Buruzula G; Deng E; Chen JT; Sari-Sarraf F; Dornelas C; Varadarajan M; Yu H; Liu C; Lim J; Hao HX; Jiang X; Malamas A; LaMarche MJ; Geyer FC; McLaughlin M; Costa C; Wagner J; Ruddy D; Jayaraman P; Kirkpatrick ND; Zhang P; Iartchouk O; Aardalen K; Cremasco V; Dranoff G; Engelman JA; Silver S; Wang H; Hastings WD; Goldoni S
    Sci Rep; 2021 Jan; 11(1):1399. PubMed ID: 33446805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
    Quintana E; Schulze CJ; Myers DR; Choy TJ; Mordec K; Wildes D; Shifrin NT; Belwafa A; Koltun ES; Gill AL; Singh M; Kelsey S; Goldsmith MA; Nichols R; Smith JAM
    Cancer Res; 2020 Jul; 80(13):2889-2902. PubMed ID: 32350067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity.
    Wang Z; Chen J; Hu J; Zhang H; Xu F; He W; Wang X; Li M; Lu W; Zeng G; Zhou P; Huang P; Chen S; Li W; Xia LP; Xia X
    J Clin Invest; 2019 Aug; 129(11):4850-4862. PubMed ID: 31408442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting SHP2 as a promising strategy for cancer immunotherapy.
    Liu Q; Qu J; Zhao M; Xu Q; Sun Y
    Pharmacol Res; 2020 Feb; 152():104595. PubMed ID: 31838080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2.
    Xu X; Hou B; Fulzele A; Masubuchi T; Zhao Y; Wu Z; Hu Y; Jiang Y; Ma Y; Wang H; Bennett EJ; Fu G; Hui E
    J Cell Biol; 2020 Jun; 219(6):. PubMed ID: 32437509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Cell-Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer.
    Chen H; Cresswell GM; Libring S; Ayers MG; Miao J; Zhang ZY; Solorio L; Ratliff TL; Wendt MK
    Cancer Res Commun; 2022 Oct; 2(10):1104-1118. PubMed ID: 36969745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatase Shp2 exacerbates intestinal inflammation by disrupting macrophage responsiveness to interleukin-10.
    Xiao P; Zhang H; Zhang Y; Zheng M; Liu R; Zhao Y; Zhang X; Cheng H; Cao Q; Ke Y
    J Exp Med; 2019 Feb; 216(2):337-349. PubMed ID: 30610104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid-specific disruption of tyrosine phosphatase Shp2 promotes alternative activation of macrophages and predisposes mice to pulmonary fibrosis.
    Tao B; Jin W; Xu J; Liang Z; Yao J; Zhang Y; Wang K; Cheng H; Zhang X; Ke Y
    J Immunol; 2014 Sep; 193(6):2801-11. PubMed ID: 25127857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 10. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
    Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
    Front Immunol; 2018; 9():2821. PubMed ID: 30555485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.
    Xu H; Van der Jeught K; Zhou Z; Zhang L; Yu T; Sun Y; Li Y; Wan C; So KM; Liu D; Frieden M; Fang Y; Mosley AL; He X; Zhang X; Sandusky GE; Liu Y; Meroueh SO; Zhang C; Wijeratne AB; Huang C; Ji G; Lu X
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33830945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.
    Liu JJ; Li Y; Chen WS; Liang Y; Wang G; Zong M; Kaneko K; Xu R; Karin M; Feng GS
    J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells.
    Okada M; Chikuma S; Kondo T; Hibino S; Machiyama H; Yokosuka T; Nakano M; Yoshimura A
    Cell Rep; 2017 Aug; 20(5):1017-1028. PubMed ID: 28768188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade.
    Zhao M; Guo W; Wu Y; Yang C; Zhong L; Deng G; Zhu Y; Liu W; Gu Y; Lu Y; Kong L; Meng X; Xu Q; Sun Y
    Acta Pharm Sin B; 2019 Mar; 9(2):304-315. PubMed ID: 30972278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The src homology 2 domain-containing tyrosine phosphatase 2 regulates primary T-dependent immune responses and Th cell differentiation.
    Salmond RJ; Huyer G; Kotsoni A; Clements L; Alexander DR
    J Immunol; 2005 Nov; 175(10):6498-508. PubMed ID: 16272304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer.
    Cai L; Duan J; Qian L; Wang Z; Wang S; Li S; Wang C; Zhao J; Zhang X; Bai H; Wang J
    Front Immunol; 2020; 11():527750. PubMed ID: 33324391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification, recombinant expression and immunological study of Lja-SHP2 in Lampetra japonica.
    Li X; Qu CM; Han YL; Liu X; Li QW
    Yi Chuan; 2020 Feb; 42(2):183-193. PubMed ID: 32102775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF-alpha induces tyrosine phosphorylation and recruitment of the Src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex.
    Bode JG; Schweigart J; Kehrmann J; Ehlting C; Schaper F; Heinrich PC; Häussinger D
    J Immunol; 2003 Jul; 171(1):257-66. PubMed ID: 12817006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
    Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
    J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.